Abstract:Objective To evaluate the efficacy and safety of Adefovir dipivoxil in the 52-week treatment of chronic hepatitis B in China.Methods We randomly assigned 480 patients with chronic hepatitis B who were positive for hepatitis B e antigen(HBeAg)in China.During the first 12-week period,480 patients were randomly to receive either 10 mg of adefovir dipivoxil(ADV)or placebo once daily in a 2:1 ratio and in the second period,all patients were accepted ADV for 18 weeks.In the last 12-week stage,all patients treated by ADV were randomly to receive either 10 mg of ADV or placebo in a 2:1 ratio and patients treated by placebo were accepted ADV.The primary end point was serum HBV DNA change during the treatment.The secondary endpoints were ALT normalization rate,HBeAg loss rate and HBeAg seroconversion rate.Results At week 12,median serum hepatitis B virus(HBV)DNA levels of group AAA(ADV-ADV-ADV)and group AAP(ADV-ADV-Placebo) were reduced 3.4 and 3.3 log copies per milliliter,significantly greater than group PAA(Placebo- ADV-ADV)of 0.1 log copies/ml reduction(P<0.05).At week 40,serum hepatitis B virus(HBV) DNA levels of all 3 groups were reduced 4.0～4.6 lg copies/ml.At week 52,median serum HBV DNA levels were reduced 5.0 and 4.5 log copies/ml in group PAA and AAA.Meanwhile,HBV DNA was reduced to level under detection in 30.3% and 28.4% patients of these 2 groups.However,HBV DNA level in group AAP rebound to baseline level and HBV DNA in only 0.8% patients(1/119)of this group was reduced to the level under detection.Alanine aminotransferase levels had normalized at week 52 in 69.2 percent and 78.6 percent of patients of groups PAA and AAA.Comparably.the ALT normalization rate reduced to 21.1%(23/109)at week 52 from 74.3%(81/109).HBeAg loss rate and HBeAg seroconversion rate at 52 week in group PAA were 200% and 17% compared with 13% and 8% in group AAA.However,the HBeAg loss rate and HBeAg seroconversion rate in group AAP were decreased from 14% and 11% at week 40 to 9% and 4% at week 52.No HBV polymerase mutations associated with resistance to ADV were identified.Only 5%～11% patients had at least one adverse event and most of which were mild to moderate.There were no significant differences in the changes in serum creatinine or serum phosphorus values compared with baseline level.Conclusions In Chinese patients with HBeAg-positive chronic hepatitis B,52 weeks of ADV treatment resulted in sig- nificant virologic,and biochemical improvement with good safety profile.No evidence of the emer- gence of adefoyir-resistant HBV polymerase mutations was found.

Nephrogenic Hypophosphatemic Osteomalacia During Adefovir Monotherapy for Chronic Hepatitis B Monoinfection.

Adefovir Dipivoxil Induced Hypophosphatemic Osteomalacia:Report of Two Cases

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series

Clinical Analysis of 11 Cases of Adefovir Dipivoxil-induced Renal Hypophosphatemia and Osteomalacia

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil

Osteomalacia Induced by Long-Term Low-Dose Adefovir Dipivoxil: Clinical Characteristics and Genetic Predictors

Follow-Up of Adefovir Dipivoxil Induced Osteomalacia: Clinical Characteristics and Genetic Predictors

Renal Safety of Adefovir Dipivoxil for Two-Year Treatment in Chinese Patients with Chronic Hepatitis B

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Persistently Elevated Urine β2-MG and Decreased BMD in a Patient with ADV-induced Hypophosphatemic Osteomalacia and Fanconi’s Syndrome After Drug Withdrawal

The clinical and pathological features of adefovir dipivoxil-related renal impairment

Fanconi syndrome complicated with spinal cord diseases and peripheral neuropathy related to adefovir dipivoxil

Clinical management of hypophosphatemic osteomalacia induced by adefovir and tenofovir: Insights from a case report

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.

Bilateral Femoral Head Necrosis And Pathological Fractures Resulted From Fanconi Syndrome Due To Adefovir Dipivoxil Treatment: A Case Report And Systematic Analysis Of 7 Cases

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China

A Retrospective Analysis of Adverse Drug Reaction Caused by Adefovir Dipivoxil

Biopsy-proven Nephrotoxicity Induced by Adefovir

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.